

PolyPid's D-PLEX100 met all key endpoints in a Phase 3 trial, showing a 38% drop in infection or death after colorectal surgery vs. standard care.
You can purchase shares of PolyPid (NASDAQ:PYPD) through any online brokerage.
Other companies in PolyPid’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
PolyPid has a consensus price target of $12.00.
The stock price for PolyPid (NASDAQ: PYPD) is $5.25 last updated October 23, 2026 at 7:55 PM EDT.
There are no upcoming dividends for PolyPid.
PolyPid does not have any upcoming earnings scheduled.
There is no upcoming split for PolyPid.
PolyPid is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating...